As of April 2023, fifty-eight patients have been treated with the drug, fifty-six (97%) with R/R AML and two (3%) ALL, with NPM1-m in twenty-five (43%) patients and KMT2Ar present in thirty-three (57%). Here, NPM1 is linked to acute myeloid leukemia.